Evidence map›Paper›PMID 42787627›Full record

ReviewAmerican journal of nuclear medicine and molecular imaging2026

FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer.

Shreeya H Gandhi, Jaskeerat Gujral, Amir A Amanullah, Om H Gandhi, Shashi B Singh, Thomas J Werner, Mona-Elisabeth Revheim, Abass Alavi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shreeya H GandhiDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Jaskeerat GujralDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Amir A AmanullahDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Om H GandhiDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Shashi B SinghDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Thomas J WernerDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.
Mona-Elisabeth RevheimThe Intervention Center, Division for Technology and Innovation, Oslo University Hospital Sognsvannsveien 20, 0372 Oslo, Norway.
Abass AlaviDepartment of Radiology, Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype accounting for 10-17% of all breast cancers, characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. TNBC is associated with high recurrence rates and poor prognosis, particularly after metastatic progression. Current surveillance guidelines rely on clinical evaluation and conventional imaging, which have limited sensitivity for detecting early recurrence. [

Indexed as

FDG PET/CThumansinflammationliver neoplasmstriple-negative breast cancer

Identifiers

PMID42787627
PMCPMC13601894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.